300482 万孚生物
已收盘 01-12 15:00:00
资讯
新帖
简况
股市必读:万孚生物(300482)预计2025年全年扣非后净利润亏损750万元至1500万元
证券之星 · 03:23
股市必读:万孚生物(300482)预计2025年全年扣非后净利润亏损750万元至1500万元
万孚生物将交上市以来最差成绩单
市场资讯 · 01-11 23:28
万孚生物将交上市以来最差成绩单
万孚生物(300482)披露2025年度业绩预告,1月9日股价上涨1.24%
证券之星 · 01-09 22:48
万孚生物(300482)披露2025年度业绩预告,1月9日股价上涨1.24%
万孚生物:预计2025年全年扣非后净利润亏损750万元至1500万元
证券之星 · 01-09 18:00
万孚生物:预计2025年全年扣非后净利润亏损750万元至1500万元
万孚生物(300482.SZ)发预减,预计2025 年度归母净利润4600万元至6900万元,下降87.71%至91.81%
智通财经 · 01-09
万孚生物(300482.SZ)发预减,预计2025 年度归母净利润4600万元至6900万元,下降87.71%至91.81%
股市必读:万孚生物(300482)1月7日董秘有最新回复
证券之星 · 01-08
股市必读:万孚生物(300482)1月7日董秘有最新回复
万孚生物:公司已制定并审议通过《市值管理制度》
证券之星 · 01-07
万孚生物:公司已制定并审议通过《市值管理制度》
万孚生物(300482)披露2025年第四季度可转换公司债券转股情况,1月5日股价上涨2.13%
证券之星 · 01-05
万孚生物(300482)披露2025年第四季度可转换公司债券转股情况,1月5日股价上涨2.13%
每周股票复盘:万孚生物(300482)拟下修可转债转股价格
证券之星 · 01-03
每周股票复盘:万孚生物(300482)拟下修可转债转股价格
万孚生物(300482)披露拟向下修正可转债转股价格议案,12月29日股价下跌0.61%
证券之星 · 2025-12-29
万孚生物(300482)披露拟向下修正可转债转股价格议案,12月29日股价下跌0.61%
股市必读:万孚生物(300482)12月25日董秘有最新回复
证券之星 · 2025-12-26
股市必读:万孚生物(300482)12月25日董秘有最新回复
万孚生物:公司目前无海南子公司
证券之星 · 2025-12-25
万孚生物:公司目前无海南子公司
万孚生物:已建立稳定的供应链体系
证券之星 · 2025-12-22
万孚生物:已建立稳定的供应链体系
万孚生物:OTC版流感检测试剂盒市场推广持续进行
证券之星 · 2025-12-22
万孚生物:OTC版流感检测试剂盒市场推广持续进行
万孚生物(300482)披露债券持有人持有公司可转债比例达到20%,12月11日股价下跌1.94%
证券之星 · 2025-12-11
万孚生物(300482)披露债券持有人持有公司可转债比例达到20%,12月11日股价下跌1.94%
万孚生物:AI辅助诊断软件获批
证券之星 · 2025-12-11
万孚生物:AI辅助诊断软件获批
万孚生物:推出一体化呼吸道病原体检测解决方案
证券之星 · 2025-12-10
万孚生物:推出一体化呼吸道病原体检测解决方案
万孚生物:公司2025年9月30日股东人数为42360户
证券之星 · 2025-12-10
万孚生物:公司2025年9月30日股东人数为42360户
万孚生物(300482)披露取得产品注册证,12月02日股价下跌1.27%
证券之星 · 2025-12-02
万孚生物(300482)披露取得产品注册证,12月02日股价下跌1.27%
万孚生物(300482)披露回购公司股份实施结果暨股份变动公告,11月24日股价上涨0.68%
证券之星 · 2025-11-24
万孚生物(300482)披露回购公司股份实施结果暨股份变动公告,11月24日股价上涨0.68%
加载更多
公司概况
公司名称:
广州万孚生物技术股份有限公司
所属行业:
医药制造业
上市日期:
2015-06-30
主营业务:
广州万孚生物技术股份有限公司的主营业务是快速诊断试剂及配套仪器的研发、生产智造、营销及服务。公司的主要产品是妊娠及优生优育检测、传染病检测、毒品(药物滥用)检测、慢性疾病检测。公司作为中国POCT领域的龙头企业公司先后荣获国家火炬计划重点高新技术企业、国家生物工程高技术产业化示范基地、国家知识产权优势企业、世界海关组织AEO高级认证企业、国家认定企业技术中心、博士后科研工作站、国家知识产权示范企业、广东省第一批制造业单项冠军企业等资质。
发行价格:
16.00
{"stockData":{"symbol":"300482","market":"SZ","secType":"STK","nameCN":"万孚生物","latestPrice":20.85,"timestamp":1768201428000,"preClose":20.42,"halted":0,"volume":9813258,"delay":0,"changeRate":0.0211,"floatShares":430000000,"shares":468000000,"eps":0.5543,"marketStatus":"已收盘","change":0.43,"latestTime":"01-12 15:00:00","open":20.21,"high":20.92,"low":20.2,"amount":202000000,"amplitude":0.0353,"askPrice":20.86,"askSize":69,"bidPrice":20.85,"bidSize":11,"shortable":0,"etf":0,"ttmEps":0.5543,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"adjPreClose":20.42,"symbolType":"stock","openAndCloseTimeList":[[1768181400000,1768188600000],[1768194000000,1768201200000]],"highLimit":22.46,"lowLimit":18.38,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":468084909,"isCdr":false,"pbRate":1.77,"roa":"--","peRate":37.61501,"roe":"2.47%","epsLYR":1.21,"committee":0.666529,"marketValue":9760000000,"turnoverRate":0.0228,"status":0,"floatMarketCap":8974000000},"requestUrl":"/m/hq/s/300482","defaultTab":"news","newsList":[{"id":"2602314550","title":"股市必读:万孚生物(300482)预计2025年全年扣非后净利润亏损750万元至1500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602314550","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602314550?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:23","pubTimestamp":1768159388,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,万孚生物报收于20.42元,上涨1.24%,换手率1.26%,成交量5.41万手,成交额1.1亿元。业绩披露要点业绩预告万孚生物发布业绩预告,预计2025年全年扣非后净利润亏损750万元至1500万元。公司公告汇总广州万孚生物技术股份有限公司2025年度业绩预告广州万孚生物技术股份有限公司发布2025年度业绩预告,预计归属于上市公司股东的净利润为4,600万元至6,900万元,同比下降87.71%至91.81%;扣除非经常性损益后的净利润为-1,500万元至-750万元,同比下降101.51%至103.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482"],"gpt_icon":0},{"id":"2602631605","title":"万孚生物将交上市以来最差成绩单","url":"https://stock-news.laohu8.com/highlight/detail?id=2602631605","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602631605?lang=zh_cn&edition=full","pubTime":"2026-01-11 23:28","pubTimestamp":1768145280,"startTime":"0","endTime":"0","summary":" 上市10年,万孚生物将交出一份上市以来业绩最差成绩单。 万孚生物近日发布的业绩预告显示,2025年预计归属净利润为4600万—6900万元,同比预降87.71%—91.81%。 此外,万孚生物方面预计,2025年扣非净利润为-750万—-1500万元,同比由盈转亏,这也将是公司上市以来首度出现扣非净利润亏损的情况。 值得一提的是,2025年,万孚生物在海外市场取得不错的成绩。万孚生物方面表示,国内市场,基层医疗市场胶体金和荧光产品线收入下滑,盈利减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-01-11/doc-inhfyhii7388867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0197","BK0046","300482","BK0239"],"gpt_icon":0},{"id":"2602323372","title":"万孚生物(300482)披露2025年度业绩预告,1月9日股价上涨1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602323372","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602323372?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:48","pubTimestamp":1767970093,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,万孚生物报收于20.42元,较前一交易日上涨1.24%,最新总市值为95.58亿元。该股当日开盘20.2元,最高20.45元,最低20.17元,成交额达1.1亿元,换手率为1.26%。公司于近日发布2025年度业绩预告,预计归属于上市公司股东的净利润为4,600万元至6,900万元,同比下降87.71%至91.81%;扣除非经常性损益后的净利润为-1,500万元至-750万元,同比下降101.51%至103.02%。具体数据以2025年年度报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900041373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300482","BK0197"],"gpt_icon":0},{"id":"2602324899","title":"万孚生物:预计2025年全年扣非后净利润亏损750万元至1500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602324899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602324899?lang=zh_cn&edition=full","pubTime":"2026-01-09 18:00","pubTimestamp":1767952836,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物发布业绩预告,预计2025年全年扣非后净利润亏损750万元至1500万元。万孚生物2025年三季报显示,前三季度公司主营收入16.9亿元,同比下降22.52%;归母净利润1.34亿元,同比下降69.32%;扣非净利润8264.16万元,同比下降78.67%;其中2025年第三季度,公司单季度主营收入4.45亿元,同比下降26.66%;单季度归母净利润-5545.91万元,同比下降169.21%;单季度扣非净利润-7090.64万元,同比下降213.09%;负债率16.42%,投资收益1374.5万元,财务费用2847.74万元,毛利率60.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900029648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482"],"gpt_icon":0},{"id":"2602269783","title":"万孚生物(300482.SZ)发预减,预计2025 年度归母净利润4600万元至6900万元,下降87.71%至91.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602269783","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602269783?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:58","pubTimestamp":1767949102,"startTime":"0","endTime":"0","summary":"智通财经APP讯,万孚生物(300482.SZ)披露2025 年度业绩预告,公司预计归属于上市公司股东的净利润4600万元至6900万元,同比下降87.71%至91.81%;扣除非经常性损益后的净亏损750万元至1500万元。公告称,公司主营业务收入同比下滑,主要原因是国内收入下滑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300482"],"gpt_icon":0},{"id":"2601388936","title":"股市必读:万孚生物(300482)1月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601388936","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601388936?lang=zh_cn&edition=full","pubTime":"2026-01-08 01:49","pubTimestamp":1767808150,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘,万孚生物报收于20.0元,下跌0.84%,换手率0.91%,成交量3.92万手,成交额7873.74万元。公司公告汇总第五届董事会第二十次会议决议公告广州万孚生物技术股份有限公司于2026年1月6日召开第五届董事会第二十次会议,审议通过补选王菊芳女士为第五届董事会独立董事、选举汪洋先生为第五届董事会非独立董事的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800000890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0046","BK0239","BK0197"],"gpt_icon":0},{"id":"2601187379","title":"万孚生物:公司已制定并审议通过《市值管理制度》","url":"https://stock-news.laohu8.com/highlight/detail?id=2601187379","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601187379?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:45","pubTimestamp":1767775510,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物(300482)01月07日在投资者关系平台上答复投资者关心的问题。投资者提问:指数创十年新高,医疗器械指数体外诊断指数再创新高,请问同行业业绩今年都下滑,但其他公司二级市场跌创新高,贵公司还在近十年新低徘徊,请问公司市值管理是否开展?万孚生物回复:尊敬的投资者您好,公司已制定并审议通过了《市值管理制度》,公司已经系统性推进市值管理各项工作。在具体实践中,公司的市值管理以提升主营业务竞争力、优化公司治理、持续提升信息披露质量等方式开展。感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700024677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0046","BK0239","BK0197"],"gpt_icon":0},{"id":"2601088033","title":"万孚生物(300482)披露2025年第四季度可转换公司债券转股情况,1月5日股价上涨2.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601088033","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601088033?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:46","pubTimestamp":1767624379,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘,万孚生物报收于20.17元,较前一交易日上涨2.13%,最新总市值为94.41亿元。近日,广州万孚生物技术股份有限公司发布关于2025年第四季度可转换公司债券转股情况的公告。公告显示,2025年10月1日至12月31日期间,万孚转债因转股减少30张,对应转股数量为111股,转股价格为27.00元/股。截至2025年12月31日,剩余可转债为5,976,850张,未转换比例为99.61%。公告还列明了可转债发行以来的历次转股价格调整情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500040561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0197","BK0239","BK0046"],"gpt_icon":0},{"id":"2600060980","title":"每周股票复盘:万孚生物(300482)拟下修可转债转股价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2600060980","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600060980?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:41","pubTimestamp":1767382869,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,万孚生物报收于19.75元,较上周的19.75元上涨0.0%。本周,万孚生物12月31日盘中最高价报19.89元。本周关注点公司公告汇总:董事会提议向下修正“万孚转债”转股价格,需提交股东大会审议。其持有公司股份174,905股,占总股本0.04%,辞职后将继续遵守股份减持相关规定。减持期间为2026年1月22日至2026年4月21日,减持价格将依据二级市场价格确定。公司董事会于2025年12月29日审议通过向下修正可转换公司债券转股价格的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300482","BK0197"],"gpt_icon":0},{"id":"2595759735","title":"万孚生物(300482)披露拟向下修正可转债转股价格议案,12月29日股价下跌0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595759735","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595759735?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:29","pubTimestamp":1767018555,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘,万孚生物报收于19.63元,较前一交易日下跌0.61%,最新总市值为91.89亿元。该股当日开盘19.76元,最高19.78元,最低19.61元,成交额达5974.42万元,换手率为0.71%。公司近日发布公告称,将于2026年1月14日召开2026年度第一次临时股东会,会议将审议《关于董事会提议向下修正可转换公司债券转股价格的议案》和《关于修订<公司章程>及相关议事规则的议案》。其中,《关于董事会提议向下修正可转换公司债券转股价格的议案》受到市场关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900037998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0046","BK0239","BK0197"],"gpt_icon":0},{"id":"2594825564","title":"股市必读:万孚生物(300482)12月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2594825564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594825564?lang=zh_cn&edition=full","pubTime":"2025-12-26 02:46","pubTimestamp":1766688371,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘,万孚生物报收于19.79元,下跌0.3%,换手率0.67%,成交量2.88万手,成交额5695.14万元。当日关注点来自交易信息汇总:12月25日主力资金净流出789.17万元,散户资金净流入1278.98万元。来自公司公告汇总:万孚生物获国家药监局批准两项医疗器械注册证,涉及全自动核酸检测系统及多联检测试剂盒。试剂盒用于体外定性检测人口咽拭子样本中的腺病毒、肺炎支原体和副流感病毒核酸。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600000895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300482","BK0197"],"gpt_icon":0},{"id":"2594233053","title":"万孚生物:公司目前无海南子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2594233053","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594233053?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:57","pubTimestamp":1766653030,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物(300482)12月25日在投资者关系平台上答复投资者关心的问题。投资者提问:请问万孚生物在海南有几家子公司?万孚生物回复:尊敬的投资者您好,公司目前无海南子公司,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500024733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300482"],"gpt_icon":0},{"id":"2593107500","title":"万孚生物:已建立稳定的供应链体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2593107500","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593107500?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:54","pubTimestamp":1766390083,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物(300482)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问:面对原材料价格波动的风险,公司是否建立了稳定的供应链体系?是否有通过长期协议、战略储备等方式来保障原材料供应并控制成本?万孚生物回复:尊敬的投资者您好,公司已经建立了稳定的供应链体系,可以通过长期协议、战略储备等方式来保障原材料供应,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200013477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0046","300482"],"gpt_icon":0},{"id":"2593102374","title":"万孚生物:OTC版流感检测试剂盒市场推广持续进行","url":"https://stock-news.laohu8.com/highlight/detail?id=2593102374","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593102374?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:36","pubTimestamp":1766389000,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物(300482)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问:公司三联检早于九安半年获美FDA认证,且有美国本地量产工厂,当前该产品在美市场渗透率、渠道覆盖(如药店/电商)及销量数据如何?先发优势是否转化为实际营收增量?万孚生物回复:尊敬的投资者您好!感谢您对公司的关注。公司美国 FDA 认证的 OTC 版流感检测试剂盒的市场推广工作在持续进行中,具体对公司营业收入的影响请留意公司定期报告,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200012815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300482","BK0197"],"gpt_icon":0},{"id":"2590146905","title":"万孚生物(300482)披露债券持有人持有公司可转债比例达到20%,12月11日股价下跌1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590146905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590146905?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:26","pubTimestamp":1765463164,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘,万孚生物报收于20.26元,较前一交易日下跌1.94%,最新总市值为94.83亿元。该股当日开盘20.7元,最高20.76元,最低20.25元,成交额达6505.94万元,换手率为0.74%。公司近日发布公告称,广州万孚生物技术股份有限公司于2020年9月1日发行6.00亿元可转换公司债券,债券简称“万孚转债”,代码123064。截至2025年12月11日收盘,优美利投资管理的证券投资基金合计持有“万孚转债”1,230,467张,占可转债发行总量的20.51%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100042011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0046","BK0239","BK0197"],"gpt_icon":0},{"id":"2590515130","title":"万孚生物:AI辅助诊断软件获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590515130?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:48","pubTimestamp":1765457290,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物(300482)12月10日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘,能不能通报一下你们公司ai医疗诊断的最新进展?万孚生物回复:尊敬的投资者您好, 公司投资的赛维森科技\"宫颈细胞数字病理图像辅助诊断软件\" 正式获批、这是全国宫颈细胞学领域首张\"Al辅助诊断\"三类产品注册证、标志着\"数字病理+Al辅诊\"模式迈向全新里程碑、 通过AI辅助阅片、显著提升诊断效率与准确性、为患者后续的诊疗提供更精准的方案、感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100038166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0197","300482"],"gpt_icon":0},{"id":"2590283302","title":"万孚生物:推出一体化呼吸道病原体检测解决方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2590283302","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590283302?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:36","pubTimestamp":1765355771,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物12月10日在投资者关系平台上答复投资者关心的问题。谢谢万孚生物回复:尊敬的投资者您好,面对流感高峰,万孚生物基于当前流感季特点,推出整合试剂、仪器与信息系统的一体化呼吸道病原体检测解决方案,旨在缩短患者等候时间,助力医疗机构平稳应对流感检测高峰。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000023809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300482","BK0046"],"gpt_icon":0},{"id":"2590302395","title":"万孚生物:公司2025年9月30日股东人数为42360户","url":"https://stock-news.laohu8.com/highlight/detail?id=2590302395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590302395?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:27","pubTimestamp":1765355243,"startTime":"0","endTime":"0","summary":"证券之星消息,万孚生物(300482)12月10日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,您好!敬请发布截至今天10月31日公司的股东户数信息万孚生物回复:尊敬的投资者您好,公司2025年9月30日股东人数为42360户,您可将股东身份证明发送至stock@wondfo.com.cn查询最新股东人数。感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000022910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0046","300482"],"gpt_icon":0},{"id":"2588051879","title":"万孚生物(300482)披露取得产品注册证,12月02日股价下跌1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588051879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588051879?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:32","pubTimestamp":1764685953,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘,万孚生物报收于20.92元,较前一交易日下跌1.27%,最新总市值为97.92亿元。该股当日开盘21.12元,最高21.22元,最低20.91元,成交额达6031.79万元,换手率为0.67%。产品注册证有效期至2030年11月3日,对公司发展具有正面影响,但目前尚无法预测其对未来营业收入的具体影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200040125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300482"],"gpt_icon":0},{"id":"2585498521","title":"万孚生物(300482)披露回购公司股份实施结果暨股份变动公告,11月24日股价上涨0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498521","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585498521?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:28","pubTimestamp":1763994485,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘,万孚生物报收于20.82元,较前一交易日上涨0.68%,最新总市值为97.46亿元。公司近日发布公告称,广州万孚生物技术股份有限公司于2025年9月23日召开董事会,审议通过回购股份方案,拟用于员工持股计划和股权激励。回购股份将用于员工持股计划或股权激励,若36个月内未使用则注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300482","BK0197"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768209112424,"stockEarnings":[{"period":"1week","weight":0.0339},{"period":"1month","weight":-0.0116},{"period":"3month","weight":-0.0607},{"period":"6month","weight":-0.0607},{"period":"1year","weight":-0.0447},{"period":"ytd","weight":0.0339}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州万孚生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42360人(较上一季度减少5.59%)","perCapita":"10160股","listingDate":"2015-06-30","address":"广东省广州市黄埔区科学城荔枝山路8号","registeredCapital":"46808万元","survey":" 广州万孚生物技术股份有限公司的主营业务是快速诊断试剂及配套仪器的研发、生产智造、营销及服务。公司的主要产品是妊娠及优生优育检测、传染病检测、毒品(药物滥用)检测、慢性疾病检测。公司作为中国POCT领域的龙头企业公司先后荣获国家火炬计划重点高新技术企业、国家生物工程高技术产业化示范基地、国家知识产权优势企业、世界海关组织AEO高级认证企业、国家认定企业技术中心、博士后科研工作站、国家知识产权示范企业、广东省第一批制造业单项冠军企业等资质。","listedPrice":16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万孚生物(300482)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万孚生物,300482,万孚生物股票,万孚生物股票老虎,万孚生物股票老虎国际,万孚生物行情,万孚生物股票行情,万孚生物股价,万孚生物股市,万孚生物股票价格,万孚生物股票交易,万孚生物股票购买,万孚生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万孚生物(300482)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}